We hypothesized that the disordered tissue architecture in cancer results from the steps that the cells execute the program designed during ontogeny in a spatiotemporally inappropriate manner. HOX genes are known as master regulators of embryonic morphogenesis, and encode transcription factors which regulate the transcription of the downstream genes to realize the program of body plan. In this study, we quantified the expression levels of 39 HOX genes in 41 human non-small cell lung cancer (non-SCLC) and non-cancerous lung tissues by a comprehensive analysis system based on the realtime RT-PCR method. We found that the expression levels of HOXA1, A5, A10 and C6 in squamous cell carcinoma tissues (and HOXA5 and A10 in adenocarcinoma tissues) were significantly higher than those in the non-cancerous tissues. Comparison of HOX gene expressions between adenocarcinoma and squamous cell carcinoma tissues showed higher expressions of HOXA1, D9, D10 and D11 in squamous cell carcinoma tissues than in adenocarcinoma tissues. Immunohistochemical analysis revealed that HOXA5 and A10 proteins were localized in the cytoplasm of tumor cells in both adenocarcinoma and squamous cell carcinoma tissues. These results suggest that the disordered patterns of HOX gene expressions were involved in not only the development of non-SCLC but also histological diversity such as adenocarcinoma and 4 squamous cell carcinoma.
INTRODUCTION
It can be hypothesized that the disordered tissue architecture in cancer results from the steps that the cells execute the program designed during ontogeny in a spatiotemporally inappropriate manner. In other words, the cancer cells may partly follow the ontogenic program to display the transformed phenotype and dynamic movement to surrounding or distant areas. Homeobox genes are a superfamily of the genes encoding transcription factors, which regulate the embryonic morphogenesis in animals (1) . The clustered group of homeobox genes in human are called HOX genes.
The genes contain a 180-bp DNA sequence (homeobox), which encodes a highly Recently, there is a growing interest in investigating relationship of inappropriate expressions of HOX genes with carcinogenesis or malignant progression.
Some HOX genes exhibit different expression levels in a variety of human cancers including kidney, colon, bladder, melanoma and prostate cancers, compared to normal tissues from which they were derived (6) (7) (8) (9) (10) . For example, HOXB5 and B9 are expressed in normal kidney but not in renal cancer whereas the expression of HOXC11 is observed in human renal cancer but not in normal kidney (6) .
In human prostate cancer, overexpression of HOXC8 correlates with loss of differentiation phenotype (10) .
Increased expressions of HOXC4, C5, C6 and C11 are likely to be involved in the development of human bladder transitional cell carcinomas (8) . We also found that the expression levels of HOXA11, A13, B9, D12 and D13 were higher in cutaneous melanoma than in nevus pigmentosus (9) .
There are few reports on HOX gene expressions in human lung cancer. The expression of some HOX genes in human small-cell lung cancers xenografted into nude mice was different from that in normal lung (11) . Analysis of HOX gene expressions by using degenerate reverse transcription-PCR showed that HOXA9, A10 and B9 were frequently up-regulated in human lung cancer cell lines and lung tumor tissues (12).
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Lechner et al. reported that some HOX genes of which expression was restricted to pulmonary embryogenesis were re-expressed in lung cancer cells (13) . To better understand the roles of HOX genes in lung cancer, we investigated the HOX gene expressions in 41 human non-small cell lung cancer tissues by a comprehensive analysis system to quantify the expressions of 39 human HOX genes based on the real-time reverse transcription-PCR method. And we further examined the relationship between HOX gene expression and clinicopathologic parameters. Histological subclassification and staging of the tumors were done by reviewing the specimens taken for pathological diagnosis, according to the TNM classification.
MATERIALS AND METHODS

Patients
The tumor status of each case was categorized based on the pTNM pathological classification of the International Union Against Cancer (14) . Pertinent major clinicopathological parameters are shown in Table 1 . real-time PCR was performed by the same method as described in our previous report (15) .
Quantitative real-time PCR. Quantitative RT-PCR assays were carried out by using ABI PRISM 7900HT (Applied Biosystems) with SYBR-green fluorescence under the same condition as described in our previous report (15) . The primer sets for amplification of 39 HOX genes and beta-actin gene were listed in our previous report (15) .
Immunohistochemistry. Surgical specimens were fixed in a 10% formalin solution and embedded by routine methods in paraffin for sectioning at a thickness of 4 microm. 
RESULTS
Expressions of HOX genes in non-cancerous tissues. Figure 1 shows the expression levels of 39 HOX genes in 15 non-cancerous lung tissues which were obtained from the surgically resected tissues of lung cancer patients. The non-cancerous tissues showed relatively high expressions of HOXB2, B3, B4, B5 and B6 which were located at 3'-side of cluster B, and HOXA3 (median values of relative expression ratio were more than 0.0025) whereas they showed relatively low or no expression of Abd-B family of HOX genes (paralog 9 to 13) which were located at 5'-side of each cluster. Generally, there was a tendency that the expression levels varied relatively in a wide range within each sample.
Differences in HOX gene expression between lung cancer and non-cancerous tissues.
We compared the expression levels of each HOX gene between lung cancer tissues and non-cancerous tissues. Four of 39 HOX genes, HOXA1, A5, A10 and C6, showed significant differences in the expression levels between cancer and noncancerous tissues (p < 0.01, Mann-Whitney U-test) (Figure 2 ). The expressions levels of all the 4 HOX genes in squamous cell carcinoma tissues were higher than those in noncancerous tissues. In adenocarcinoma tissues, the expression levels of HOXA5 and A10 were high compared to non-cancerous tissues. We also found significant differences in the expression levels between squamous cell carcinoma tissues and adenocarcinoma tissues: HOXA1, D9, D10 and D11 showed higher expressions in squamous cell carcinoma than in adenocarcinoma tissues ( Figure 3 ). 
Immunohistochemical examination for HOXA5 and A10 in non-SCLC specimens.
We subjected non-SCLC tissues and their adjacent non-cancerous tissues of 8 specimens (4 adenocarcinoma and 4 squamous cell carcinoma) to immunohistochemical staining to detect the protein expression of HOXA5 and A10 of which expressions were higher at mRNA levels in non-SCLC than non-cancerous tissues. .
DISCUSSION
In this study, we tried to elucidate whether inappropriate expressions of HOX genes were involved in the development and progression of non-small cell lung cancer (non- Homeodomain of HOX proteins bind to CREB binding protein (CBP) and block its acetyltransferase activity (19) . These indicate that HOX proteins modulate the transcriptional activity through interaction with other proteins in a non-DNA binding manner. Therefore, we need to consider a possibility that HOXA5 and A10 proteins interfere with the function of anti-oncogenic molecules in lung cancer cells.
It is known that HOXA1 and C6, which were upregulated in squamous cell carcinoma, affect the cell growth and death. Forced expression of HOXA1 in human breast cancer cells results in increased cell growth activity (20) . Loss of HOXC6 expression by transfection with siRNA induces apoptosis in human prostate cancer cell lines (21) . Therefore, the increased expressions of HOXA1 and C6 may play a promoting role in the primary growth of lung squamous cell carcinoma tissues.
Between adenocarcinoma and squamous cell carcinoma, 4 HOX genes presented different expressions. The expression levels of HOXA1, D9, D10 and D11 were significantly higher in squamous cell carcinoma than in adenocarcinoma. The expression levels of HOXD12 and D13 also tended to be high in squamous cell carcinoma (p = 0.05 and 0.01, respectively, Mann-Whitney U-test, data not shown). We examined the relationship between the expression of these HOX genes, and SCC and CYFRA21-1 which were tumor markers of lung squamous cell carcinoma. There was no relationship between them. As the expressions of HOXA1 and HOXD9-11 genes were also upregulated in oral squamous cell carcinoma (our unpublished data), these HOX genes are likely involved in maintaining the squamous cell carcinoma-related phenotypes other than SCC and CYFRA21-1.
We found a positive correlation between CEA levels and HOXD3 or D4 expression levels although their correlation coefficients were not so high. There are many 15 common phenomena between cancer and embryonic morphogenesis, one of which is the production of oncofetal proteins. This evidence provides us the possibility to consider HOX genes as candidates which regulate the production of oncofetal proteins.
In conclusion, the results presented here suggest that the disordered patterns of HOX gene expressions were involved not only in the development of non-SCLC but also in the histologically aberrant diversity such as adenocarcinoma and squamous cell carcinoma. Tumor marker, median (range) CEA (ng/ml) SCC (ng/ml) NSE (ng/ml) CYFRA21-1 (ng/ml) ProGRP (pg/ml) Adenocarcinoma (n = 28) Sqaumous cell carcinoma (n = 13)
